One of Canada’s largest cannabis operators has partnered up with a pharmaceutical company for a new medical CBD product.
What’s happening:
- Aurora Cannabis (NASDAQ: ACB) and Vectura Fertin Pharma have officially launched a new novel CBD lozenge for medical patients in Canada known as the Luo CBD lozenge
Why it matters:
- The new CBD lozenge represents the first ever launch of a medical cannabis product developed by Vectura Fertin Pharma in Canada
- Vectura Fertina Pharma is owned by tobacco giant Phillip Morris International and is focused on developing potential new breakthrough products in cannabinoids, inhaled therapeutics and nicotine replacements
Going deeper:
- Aurora Cannabis will begin selling and distributing the new CBD lozenge to their existing medical patients in Canada and will also make it available to be prescribed by Canadian doctors
- Aurora Cannabis has the largest medical patient platform for cannabis in all of Canada and is one of the largest publicly traded medical cannabis operators globally
The intrigue:
- Phillip Morris has been quietly making a big push into cannabis, previously agreeing to acquire Israeli medical cannabis company Syqe Medical and fund their final clinical trials for their novel medical device with the United States Food and Drug Association
